Early Warning Report Issued Pursuant to National Instrument 62-103 in Respect of the Acquisition of Shares of Abattis Bioceuticals Corp.admin
In accordance with regulatory requirements, Mr. Michael Withrow, the President, CEO, and a director of Abattis Bioceuticals Corp. (CNSX: FLU) ("Abattis"), announces that he has recently acquired, directly or indirectly, 1,500,000 shares of Abattis as a result of a Shares for Debt Agreement.
Prior to such acquisition, Mr. Withrow held, directly or indirectly or had control over, 7,240,300 common shares and 330,000 warrants of Abattis, each of which warrants entitle the holder to acquire one common share in the capital of Abattis. In addition, Mr. Withrow holds an aggregate of 690,000 options to acquire
690,000 common shares of Abattis.
Mr. Withrow currently holds or exercises control or direction over an aggregate of 8,740,300 common shares of Abattis that represent an interest of 26.0% of Abattis‘ issued and outstanding capital at the date hereof on a non–diluted basis.
Assuming the exercise of all warrants and options held by him or over which he has control or direction, Mr. Withrow will hold or exercise control or direction over an aggregate of 10,760,300 common shares of Abattis that represent an interest of 32.0% of Abattis‘ issued and outstanding capital at the date hereof, on a partially diluted basis.
The securities acquired by Mr. Withrow referred to above are held for investment purposes only. These investments will be reviewed on a continuing basis and holdings may be increased or decreased in the future.
" Mike Withrow"
Posted: February 4th, 2014 under ACCESSWIRE.